中文摘要：

目的探讨细胞外信号调节激酶（Extracellular regulated kinase,ERK）的磷酸化水平与肺癌细胞生物学行为及化疗患者预后的关系。方法采用双染免疫组化检测50例非小细胞肺癌（NACLC）组织中ERK1/2和p-ERK1/2的表达,并分析二者与肺癌生物学行为、化疗疗效、患者生存期的关系。结果 50例肺癌标本ERK1/2阳性率62.0%,p-ERK1/2阳性率46.0%;ERK1/2和p-ERK1/2分化低、有淋巴结转移的肺癌表达明显升高,p-ERK1/2水平还与临床分期密切相关;ERK1/2和p-ERK1/2表达与肺癌化疗疗效有关,ERK1/2和p-ERK1/2阳性组肺癌治疗有效率明显低于相应的阴性组肺癌;Kaplan-Meier生存曲线及log-rank分析发现,p-ERK1/2表达水平与肺癌患者总生存期（OS）和无瘤生存期（DFS）明显相关,p-ERK1/2高表达组肺癌患者OS和DFS比阴性组肺癌缩短,而ERK1/2与患者OS和DFS无明显相关。结论肺癌组织存在ERK1/2信号蛋白激活现象,ERK1/2被激活后的磷酸化水平能够反映肺癌的生物学行为,并对患者的预后判断有一定帮助。

英文摘要：

Objective To investigate the relationship between the phosphorylation level of extracellular regulated kinase 1/2（ERK1/2） in non-small cell lung cancer（NSCLC） and the prognosis of NSCLC patients after chemotherapy.Methods 50 cases of NSCLC specimens were collected and examined the expression levels of total ERK1/2 and phosphorylated ERK1/2（p-ERK1/2） by dual-staining immunohistochemistry,and the relationship between the phosphorylation level of ERK1/2 and the outcome of chemotherapy,the prognosis of NSCLC patients were analyzed statistically.Results The positive rates of ERK1/2 and p-ERK1/2 in NSCLC were 62.0% and 46.0%,respectively.The expression levels of ERK1/2 and p-ERK1/2 were higher in NSCLC with poor differentiation and lymph node metastasis,specially the expression level of p-ERK1/2 was also correlated to clinic late stage.Over-expression of ERK1/2 and p-ERK1/2 was correlated closely to poor chemotherapeutic outcome of NSCLC patients.Kaplan-Meier curve and log-rank analysis showed the expression level of p-ERK1/2 was correlated closely to overall survival（OS） and disease-free survival（DFS） of NSCLC patients,the patients with over-expression of p-ERK1/2 had shorter OS and DFS than that with negative expression of p-ERK1/2.Whereas,expression of ERK1/2 was not correlated to OS and DFS of NSCLC patients.Conclusion ERK1/2 signailing pathway is activated in NSCLC,the phosphorylation level of ERK1/2 can reflect the NSCLC biological characteristics and will help us to judge the prognosis of NSCLC patients after chemotherapy.